RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton and Chief Financial Officer and Chief Business Officer Adam Levy will participate in a fireside chat at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 5 p.m. PT
The live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days.
Bank of America Securities 2023 Health Care Conference:
| Date: | Wednesday, May 10, 2023 |
| Time: | 5:00 p.m. PT |
About Mineralys
Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension.
Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.
Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$40.74 |
| Daily Change: | -2.38 -5.52 |
| Daily Volume: | 1,236,085 |
| Market Cap: | US$3.220B |
November 10, 2025 November 07, 2025 September 30, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
